Shire PLC (NASDAQ:SHPG) – Stock analysts at William Blair cut their Q3 2018 earnings per share estimates for Shire in a research report issued to clients and investors on Thursday. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings per share of $3.71 for the quarter, down from their previous estimate of $4.07. William Blair also issued estimates for Shire’s Q4 2018 earnings at $4.14 EPS.
SHPG has been the subject of a number of other reports. Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a research report on Friday, January 5th. Royal Bank of Canada set a $192.00 price target on Shire and gave the company a “buy” rating in a research report on Monday, February 5th. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Piper Jaffray Companies restated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Finally, B. Riley dropped their price target on Shire from $201.00 to $181.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $209.23.
Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. The business had revenue of $4.14 billion during the quarter, compared to analyst estimates of $4.01 billion. Shire had a return on equity of 14.75% and a net margin of 28.17%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.37 earnings per share.
A number of institutional investors have recently modified their holdings of SHPG. Harding Loevner LP grew its position in Shire by 18,894.4% in the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after acquiring an additional 126,865,607 shares during the period. Third Point LLC acquired a new position in Shire during the third quarter worth $183,768,000. Boston Partners lifted its stake in Shire by 60.9% during the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after purchasing an additional 886,572 shares in the last quarter. ING Groep NV lifted its stake in Shire by 9,043.1% during the fourth quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock worth $81,366,000 after purchasing an additional 518,800 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its stake in Shire by 26,182.4% during the third quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after purchasing an additional 472,592 shares in the last quarter. Institutional investors own 20.74% of the company’s stock.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a $0.8937 dividend. This represents a yield of 1.33%. This is a positive change from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. Shire’s dividend payout ratio is presently 4.20%.
WARNING: “Q3 2018 EPS Estimates for Shire PLC (SHPG) Reduced by William Blair” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/19/q3-2018-eps-estimates-for-shire-plc-shpg-reduced-by-william-blair.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.